2020 专家共识:非小细胞肺癌的新辅助免疫治疗

2020-12-30 中国肿瘤科相关专家小组(统称) Transl Lung Cancer Res . 2020 Dec;9(6):2696-2715.

肺癌是全球范围内导致癌症相关死亡的主要原因,为了更好地指导我国胸外科医师开展非小细胞肺癌的新辅助免疫治疗,国内知名胸外科医生对新辅助免疫治疗的热点话题和争议性问题进行了深入探讨,结合新辅助免疫治疗的最

中文标题:

2020 专家共识:非小细胞肺癌的新辅助免疫治疗

英文标题:

Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer

发布日期:

2020-12-30

简要介绍:

肺癌是全球范围内导致癌症相关死亡的主要原因,为了更好地指导我国胸外科医师开展非小细胞肺癌的新辅助免疫治疗,国内知名胸外科医生对新辅助免疫治疗的热点话题和争议性问题进行了深入探讨,结合新辅助免疫治疗的最新证据,形成了非小细胞肺癌新辅助免疫治疗的专家共识。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=2020 专家共识:非小细胞肺癌的新辅助免疫治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=111cc1c0020a6222, title=2020 专家共识:非小细胞肺癌的新辅助免疫治疗, enTitle=Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer, guiderFrom=Transl Lung Cancer Res . 2020 Dec;9(6):2696-2715., authorId=0, author=, summary=肺癌是全球范围内导致癌症相关死亡的主要原因,为了更好地指导我国胸外科医师开展非小细胞肺癌的新辅助免疫治疗,国内知名胸外科医生对新辅助免疫治疗的热点话题和争议性问题进行了深入探讨,结合新辅助免疫治疗的最, cover=https://img.medsci.cn/2021130/1611940923630_2020535.jpg, journalId=0, articlesId=null, associationId=747, associationName=中国肿瘤科相关专家小组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Wed Dec 30 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>肺癌是全球范围内导致癌症相关死亡的主要原因,为了更好地指导我国胸外科医师开展非小细胞肺癌的新辅助免疫治疗,国内知名胸外科医生对新辅助免疫治疗的热点话题和争议性问题进行了深入探讨,结合新辅助免疫治疗的最新证据,形成了非小细胞肺癌新辅助免疫治疗的专家共识。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=276, tagName=非小细胞肺癌), TagDto(tagId=1246, tagName=免疫治疗)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=276, guiderKeyword=非小细胞肺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5029, appHits=334, showAppHits=0, pcHits=1680, showPcHits=4695, likes=1, shares=28, comments=23, approvalStatus=1, publishedTime=Sat Jan 30 01:46:59 CST 2021, publishedTimeString=2020-12-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sat Jan 30 01:22:10 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Thu Jan 04 12:27:09 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 专家共识:非小细胞肺癌的新辅助免疫治疗.pdf)])
2020 专家共识:非小细胞肺癌的新辅助免疫治疗.pdf
下载请点击:
评论区 (17)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1208586, encodeId=4e2712085864b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00ec8098175, createdName=ms3000000771933475, createdTime=Mon Apr 04 18:49:54 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193334, encodeId=4c2911933342e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=082a2068724, createdName=irene_wang, createdTime=Mon Feb 14 16:44:01 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084383, encodeId=7ac8108438344, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Sun Dec 26 11:42:07 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051804, encodeId=ba151051804ea, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Lxm68IBuibT4r8dENb6c3ZhEMM1O1lQ6I4FW42fEEE7rIskicQCsqCMdfI6TUQnOWAzMQnajiaD9z6yLck7UD1X3A/132, createdBy=64722506333, createdName=前无, createdTime=Thu Sep 16 09:10:09 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005700, encodeId=4e3a1005e005e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b0b2382365, createdName=123170b1m40暂无昵称, createdTime=Fri Aug 06 22:28:06 CST 2021, time=2021-08-06, status=1, ipAttribution=)]
    2022-04-04 ms3000000771933475

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1208586, encodeId=4e2712085864b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00ec8098175, createdName=ms3000000771933475, createdTime=Mon Apr 04 18:49:54 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193334, encodeId=4c2911933342e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=082a2068724, createdName=irene_wang, createdTime=Mon Feb 14 16:44:01 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084383, encodeId=7ac8108438344, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Sun Dec 26 11:42:07 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051804, encodeId=ba151051804ea, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Lxm68IBuibT4r8dENb6c3ZhEMM1O1lQ6I4FW42fEEE7rIskicQCsqCMdfI6TUQnOWAzMQnajiaD9z6yLck7UD1X3A/132, createdBy=64722506333, createdName=前无, createdTime=Thu Sep 16 09:10:09 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005700, encodeId=4e3a1005e005e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b0b2382365, createdName=123170b1m40暂无昵称, createdTime=Fri Aug 06 22:28:06 CST 2021, time=2021-08-06, status=1, ipAttribution=)]
    2022-02-14 irene_wang

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1208586, encodeId=4e2712085864b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00ec8098175, createdName=ms3000000771933475, createdTime=Mon Apr 04 18:49:54 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193334, encodeId=4c2911933342e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=082a2068724, createdName=irene_wang, createdTime=Mon Feb 14 16:44:01 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084383, encodeId=7ac8108438344, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Sun Dec 26 11:42:07 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051804, encodeId=ba151051804ea, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Lxm68IBuibT4r8dENb6c3ZhEMM1O1lQ6I4FW42fEEE7rIskicQCsqCMdfI6TUQnOWAzMQnajiaD9z6yLck7UD1X3A/132, createdBy=64722506333, createdName=前无, createdTime=Thu Sep 16 09:10:09 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005700, encodeId=4e3a1005e005e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b0b2382365, createdName=123170b1m40暂无昵称, createdTime=Fri Aug 06 22:28:06 CST 2021, time=2021-08-06, status=1, ipAttribution=)]
    2021-12-26 未来将来

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1208586, encodeId=4e2712085864b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00ec8098175, createdName=ms3000000771933475, createdTime=Mon Apr 04 18:49:54 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193334, encodeId=4c2911933342e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=082a2068724, createdName=irene_wang, createdTime=Mon Feb 14 16:44:01 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084383, encodeId=7ac8108438344, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Sun Dec 26 11:42:07 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051804, encodeId=ba151051804ea, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Lxm68IBuibT4r8dENb6c3ZhEMM1O1lQ6I4FW42fEEE7rIskicQCsqCMdfI6TUQnOWAzMQnajiaD9z6yLck7UD1X3A/132, createdBy=64722506333, createdName=前无, createdTime=Thu Sep 16 09:10:09 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005700, encodeId=4e3a1005e005e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b0b2382365, createdName=123170b1m40暂无昵称, createdTime=Fri Aug 06 22:28:06 CST 2021, time=2021-08-06, status=1, ipAttribution=)]
    2021-09-16 前无

    学习中

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1208586, encodeId=4e2712085864b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00ec8098175, createdName=ms3000000771933475, createdTime=Mon Apr 04 18:49:54 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193334, encodeId=4c2911933342e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=082a2068724, createdName=irene_wang, createdTime=Mon Feb 14 16:44:01 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084383, encodeId=7ac8108438344, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Sun Dec 26 11:42:07 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051804, encodeId=ba151051804ea, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Lxm68IBuibT4r8dENb6c3ZhEMM1O1lQ6I4FW42fEEE7rIskicQCsqCMdfI6TUQnOWAzMQnajiaD9z6yLck7UD1X3A/132, createdBy=64722506333, createdName=前无, createdTime=Thu Sep 16 09:10:09 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005700, encodeId=4e3a1005e005e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b0b2382365, createdName=123170b1m40暂无昵称, createdTime=Fri Aug 06 22:28:06 CST 2021, time=2021-08-06, status=1, ipAttribution=)]
    2021-08-06 123170b1m40暂无昵称

    学习

    0

拓展阅读

ASCO指南:IV期非小细胞肺癌的维持治疗(2009)

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2009-12-20

2010CCO 晚期非小细胞肺癌一线全身化疗

加拿大安大略癌症治疗中心(CCO,Cancer Care Ontario) · 2010-01-01

2010ESMO临床实践指南:早期和局部晚期(非转移性)非小细胞肺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-03-01

2010ESMO临床实践指南:转移性非小细胞肺癌的诊断、治疗和随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-03-01